# Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer

Source: https://onco.cc/trials/nct07745296/  
OnCo record `nct07745296` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of zanidatamab, capecitabine, futibatinib and ivosidenib in gallbladder cancer and other biliary tract cancers, run by UNICANCER, not yet recruiting.

## Summary

Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer is a phase 3, randomised interventional study registered as NCT07745296 by UNICANCER, with a registry enrolment figure of 990 participants, started 2027-01-02 and due to reach its primary completion in 2033-07-02. Interventions recorded: Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine, Capecitabine (Xeloda). Conditions listed: Biliary Tract Cancer (BTC). Gallbladder cancer is named in the registry entry: "2. Histologically-proven intrahepatic cholangiocarcinoma, perihilar or distal extrahepatic cholangiocarcinoma or gallbladder carcinoma (ampullary carcinoma is excluded)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: SAFIR-IMPACT
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07745296
- Phase: 3
- Setting: Investigating Precision Medicine in the Adjuvant Setting: a Phase 3 Clinical Trial in Biliary Tract Cancer
- Sponsor: UNICANCER
- Enrolled: 990

## Sources

- ClinicalTrials.gov NCT07745296: https://clinicaltrials.gov/study/NCT07745296

## Connected records

- cancers: [Ampullary cancer (ampulla of Vater)](https://onco.cc/cancers/ampullary/), [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IDH inhibitors](https://onco.cc/technologies/idh-inhibitors/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Futibatinib](https://onco.cc/drugs/futibatinib/), [Ivosidenib](https://onco.cc/drugs/ivosidenib/), [Zanidatamab](https://onco.cc/drugs/zanidatamab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07745296.json